Wave Life Sciences Ltd. (WVE) CEO gets 1M options, sells shares for tax

Filing Impact

(High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Wave Life Sciences Ltd. insider activity: President and CEO Paul Bolno received 165,000 restricted share units on February 5, 2026, bringing his direct holdings to 286,000 ordinary shares. These RSUs vest in four equal annual installments from February 8, 2027 through February 8, 2030.

On February 9, 2026, he sold 10,480 ordinary shares at $13.45 each solely to cover taxes from RSU vesting, leaving 275,520 shares owned directly. He also received a stock option for 1,000,000 ordinary shares at a $12.75 exercise price, vesting 25% on February 8, 2027 and 6.25% quarterly until February 8, 2030.

Insider Trade Summary

Net Seller: 10,480 shares ($140,956)

Net Sell 3 txns

Insider BOLNO PAUL

Role President and CEO

Sold 10,480 shs ($141K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	10,480	$13.45	$141K
Grant/Award	Share Option (right to buy)	1,000,000	$0.00	--
Grant/Award	Ordinary Shares	165,000	$0.00	--

Holdings After Transaction: Ordinary Shares — 275,520 shares (Direct); Share Option (right to buy) — 1,000,000 shares (Direct)

Footnotes (1)

Consists of restricted share units (RSUs). The RSUs vest in four equal annual installments of 25% on February 8, 2027 through February 8, 2030. On February 9, 2026, the reporting person sold 10,480 ordinary shares solely to cover taxes associated with the vesting of restricted share units ("RSUs") on February 8, 2026. These sales were made pursuant to a provision in the reporting person's RSU agreement that requires automatic sales of shares to cover tax withholding obligations. The option vests as to 25% of the shares on February 8, 2027, and vests as to an additional 6.25% of the shares quarterly thereafter until February 8, 2030.

Form 4 Insider Transactions: What Each Field Means →

02/11/2026 - 09:02 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BOLNO PAUL

(Last)

(First)

(Middle)

C/O WAVE LIFE SCIENCES LTD.,

733 CONCORD AVE.

(Street)

CAMBRIDGE

02138

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Wave Life Sciences Ltd. [ WVE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
02/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Ordinary Shares	02/05/2026		A		165,000⁽¹⁾	A	$0	286,000	D
Ordinary Shares	02/09/2026		S⁽²⁾		10,480	D	$13.45	275,520	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Share Option (right to buy)	$12.75	02/05/2026		A		1,000,000		⁽³⁾	02/05/2036	Ordinary Shares	1,000,000	$0	1,000,000	D

Explanation of Responses:

1. Consists of restricted share units (RSUs). The RSUs vest in four equal annual installments of 25% on February 8, 2027 through February 8, 2030.

2. On February 9, 2026, the reporting person sold 10,480 ordinary shares solely to cover taxes associated with the vesting of restricted share units ("RSUs") on February 8, 2026. These sales were made pursuant to a provision in the reporting person's RSU agreement that requires automatic sales of shares to cover tax withholding obligations.

3. The option vests as to 25% of the shares on February 8, 2027, and vests as to an additional 6.25% of the shares quarterly thereafter until February 8, 2030.

	/s/ Paul B. Bolno	02/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Wave Life Sciences (WVE) CEO Paul Bolno report?

Paul Bolno reported three transactions: a grant of 165,000 restricted share units, a grant of options on 1,000,000 ordinary shares, and the sale of 10,480 shares. The sale was executed solely to cover tax withholding tied to RSU vesting.

How many Wave Life Sciences (WVE) RSUs were granted to Paul Bolno and how do they vest?

Paul Bolno received 165,000 restricted share units. These RSUs vest in four equal annual installments of 25% each, starting on February 8, 2027 and continuing annually through February 8, 2030, aligning his compensation with longer-term company performance.

Why did Paul Bolno sell 10,480 Wave Life Sciences (WVE) shares?

He sold 10,480 ordinary shares on February 9, 2026 solely to cover taxes from RSU vesting. The RSU agreement requires automatic share sales to satisfy tax withholding obligations, so this transaction reflects tax management rather than a discretionary portfolio decision.

What are the key terms of Paul Bolno’s 1,000,000 Wave Life Sciences (WVE) stock options?

Bolno was granted options on 1,000,000 ordinary shares with a $12.75 exercise price. The option vests 25% on February 8, 2027, then 6.25% of the shares vest quarterly until February 8, 2030, creating a multi-year incentive schedule.

How many Wave Life Sciences (WVE) shares does Paul Bolno own after these transactions?

After the reported transactions, Paul Bolno directly owns 275,520 ordinary shares. This figure reflects the grant of 165,000 restricted share units and the sale of 10,480 shares to cover taxes, as detailed in the Form 4 filing.

When will Paul Bolno’s new Wave Life Sciences (WVE) equity awards fully vest?

The 165,000 RSUs vest in four annual 25% installments from February 8, 2027 through February 8, 2030. The 1,000,000-share option vests 25% on February 8, 2027, then 6.25% quarterly, also completing its vesting schedule on February 8, 2030.